98,749 Shares in Abbott Laboratories $ABT Purchased by PBU The Pension Fund of Early Childhood & Youth Educators

PBU The Pension Fund of Early Childhood & Youth Educators acquired a new position in shares of Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 98,749 shares of the healthcare product maker’s stock, valued at approximately $12,372,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABT. MidAtlantic Capital Management Inc. purchased a new stake in Abbott Laboratories in the 4th quarter valued at about $25,000. Harbor Capital Advisors Inc. purchased a new stake in Abbott Laboratories in the 4th quarter valued at about $27,000. Bridge Generations Wealth Management LLC purchased a new stake in Abbott Laboratories in the 3rd quarter valued at about $33,000. Leonteq Securities AG purchased a new stake in Abbott Laboratories in the 4th quarter valued at about $35,000. Finally, Turning Point Benefit Group Inc. purchased a new stake in Abbott Laboratories in the 3rd quarter valued at about $39,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on ABT. TD Cowen lowered their price target on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Leerink Partners lowered their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a report on Tuesday, April 21st. Barclays lowered their price target on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a report on Monday, April 20th. Argus lowered their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Finally, JPMorgan Chase & Co. lowered their price target on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $119.09.

Abbott Laboratories Stock Performance

NYSE ABT opened at $91.20 on Friday. The firm has a market capitalization of $158.85 billion, a P/E ratio of 25.55, a P/E/G ratio of 1.51 and a beta of 0.63. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The business’s 50-day simple moving average is $92.80 and its 200-day simple moving average is $109.31.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Insider Activity

In related news, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ? increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.